Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
CLINDAMYCIN (CLINDAMYCIN PHOSPHATE)
PFIZER CANADA ULC
J01FF01
CLINDAMYCIN
150MG
SOLUTION
CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 150MG
INTRAMUSCULAR
2/4/6/60 ML
Prescription
LINCOMYCINS
Active ingredient group (AIG) number: 0105830002; AHFS:
APPROVED
2003-10-06
_DALACIN C PHOSPHATE (clindamycin phosphate)- Product Monograph _ _Page 1 of 38_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR DALACIN ® C PHOSPHATE clindamycin injection USP 150 mg/mL (as clindamycin phosphate) Sterile Solution Antibiotic Pfizer Canada ULC 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Initial Authorization: OCT 05, 1972 Date of Revision: JAN 10, 2022 Submission Control Number: 255973 ® Pfizer Enterprises, SARL Pfizer Canada ULC, Licensee © Pfizer Canada ULC 2021 _ _ _DALACIN C PHOSPHATE (clindamycin phosphate)- Product Monograph _ _Page 2 of 38_ RECENT MAJOR LABEL CHANGES [4 DOSAGE AND ADMINISTRATION], [4.2 Recommended Dose and Dosage Adjustment] [01/2022] [7 WARNINGS AND PRECAUTIONS], [Renal] [01/2022] TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .......................................................................................................... 5 1.2 Geriatrics........................................................................................................... 5 2 CONTRAINDICATIONS ................................................................................................. 5 4 DOSAGE AND ADMINISTRATION................................................................................. 5 4.1 Dosing Considerations ....................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment........................................... Soma hati kamili